Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

3.201 +0.001 (+0.03%)
Streaming Delayed Price Updated: 11:17 AM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)
From ADC Therapeutics SA
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022
Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago... 
Via Benzinga
Analyst Ratings for ADC Therapeutics
Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter: 
Via Benzinga
Expert Ratings for ADC Therapeutics
ADC Therapeutics (NYSE:ADCT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
ADC Therapeutics: Q2 Earnings Insights
  ADC Therapeutics (NYSE:ADCT) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
From ADC Therapeutics SA
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
ADC Therapeutics, Sobi Ink European Licensing Pact For Lymphoma Drug
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Upgrades 
Via Benzinga
Where ADC Therapeutics Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on ADC Therapeutics (NYSE:ADCT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
ADC Therapeutics to Participate in Morgan Stanley’s 20th Annual Global Healthcare Conference
From ADC Therapeutics
Via Business Wire
AMC Entertainment, Pharvaris And Some Other Big Stocks Moving Lower On Monday
  
Via Benzinga
ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
Earnings Outlook For ADC Therapeutics
  ADC Therapeutics (NYSE:ADCT) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. Analysts estimate that ADC... 
Via Benzinga
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results. 
Via Benzinga
ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, 2022
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Rituximab in First-Line Diffuse Large B-Cell Lymphoma
From ADC Therapeutics SA
Via Business Wire
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial
From ADC Therapeutics SA
Via Business Wire
Why ADC Therapeutics Shares Are Rising Today
ADC Therapeutics SA (NYSE: ADCT) shares are trading higher by 11.56% to $10.23 Friday afternoon after the company entered into an exclusive license agreement with Swedish Orphan Biovitrum for the... 
Via Benzinga
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents
From ADC Therapeutics SA
Via Business Wire
HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications
 
Via Benzinga
ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma
From ADC Therapeutics
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.